All Posts By

Smartkarma Daily Briefs

Daily Brief TMT/Internet: Samsung Electronics Pref Shares, NVIDIA Corp, ROHM Co Ltd, Canon Electronics, Kingsoft Corp, Unity Software , DiDi Global, Bentley Systems , Nippo Ltd, Qualcomm Inc and more

By | Daily Briefs, TMT/Internet

In today’s briefing:

  • Korea Dividend Tax Cut: Eligibility Criteria & Market Impact on Large Caps, Including Samsung Prefs
  • NVIDIA. Burry’s Claims Miss The Forest For The Trees. The Real Issues Are Structural, Not Legal
  • Shortlist Of High Conviction Ideas Across China, Japan, India – November 2025
  • Canon Electronics (7739 JP): Canon (7751 JP)’s Tender Offer at JPY3,650
  • Tencent/Netease: Zero Approval in November Despite Game Approvals at New High
  • Unity Software: Its Fast-Growing Ad Empire Is Grabbing Eyeballs But THESE Are The 4 Major Challenges Ahead!
  • Didi Global Q325 Results | China Solid, But International Goes From Bad to Worse | How to Fix?
  • Bentley Systems Is Riding a New Wave of AI-Driven Engineering Power—How Long Will It Last?
  • NIPPO LTD. (9913 JP): RESEARCH UPDATE
  • Qualcomm’s IoT Empire Is Booming — Can Arduino Supercharge Its $14B Vision?


Korea Dividend Tax Cut: Eligibility Criteria & Market Impact on Large Caps, Including Samsung Prefs

By Sanghyun Park

  • Market eyed 25% top rate, but 30% is still punchy; <100 people hit it, lower than before, giving big shareholders incentive to rotate back into dividends.
  • The new regime hits only companies with 25% payout last year and +10% YoY dividend: lower than the original draft, and the 10% bump is a solid positive.
  • Companies >5tn KRW with ≥25% payout last year must boost dividends +10% YoY to get the tax cut; Samsung could add ~1tn KRW, potentially easing its pref discount.

NVIDIA. Burry’s Claims Miss The Forest For The Trees. The Real Issues Are Structural, Not Legal

By William Keating

  • After taking short positions against Palantir & NVIDIA, Michael Burry has closed his hedge fund and taken to substack to continue his assault on the AI bubble
  • While he makes some valid points, these are mainly things everybody already knows and in the end he’s missing the forest for the trees
  • There are key structural issues surrounding the AI Infrastructure build out (grid, foundry, memory capacity to mention a few). These will drive course corrections, all by themselves.

Shortlist Of High Conviction Ideas Across China, Japan, India – November 2025

By Sreemant Dudhoria,CFA


Canon Electronics (7739 JP): Canon (7751 JP)’s Tender Offer at JPY3,650

By Arun George

  • Canon Electronics (7739 JP) has recommended a tender offer from Canon Inc (7751 JP) at JPY3,650, a 32.4% premium to the last close price.
  • The offer is attractive as it is above book value (P/B of 1.21x), above the midpoint of the IFA DCF valuation range and represents an all-time high. 
  • An attractive offer facilitates meeting the required tendering rate. The offer closes on 19 January 2026 and is a done deal. 

Tencent/Netease: Zero Approval in November Despite Game Approvals at New High

By Ke Yan, CFA, FRM

  • China announced game approval for the November batch. The number of games approved remained at a higher level than 2023.
  • The pace of China game approval appears to have accelerated to above the pre-tightening level.
  • Of the companies that we are monitoring, while market leader Tencent and Netease didn’t obtained approval, Kingsoft and Bilibili obtained approval for one game each.

Unity Software: Its Fast-Growing Ad Empire Is Grabbing Eyeballs But THESE Are The 4 Major Challenges Ahead!

By Baptista Research

  • Unity Technologies reported strong results for the third quarter of 2025, surpassing both its own guidance and market expectations.
  • The company demonstrated robust growth in its key segments, particularly in Grow, driven by the high performance of its Vector AI, and its Create segment also saw significant year-over-year growth.
  • Positively, Unity’s Grow segment, which includes its Vector AI, experienced an 11% quarter-over-quarter increase.

Didi Global Q325 Results | China Solid, But International Goes From Bad to Worse | How to Fix?

By Daniel Hellberg

  • Didi’s China business showed solid Y/Y growth, but International worsened dramatically
  • Spending on Sales & Marketing (including incentives) was up CNY 1.7 bn Y/Y, or +55%
  • Should it seek an IPO soon, Didi will have to show a path to profits for International segment

Bentley Systems Is Riding a New Wave of AI-Driven Engineering Power—How Long Will It Last?

By Baptista Research

  • Bentley Systems’ third-quarter results for 2025 reflect a company aligning its strategic initiatives with the growing demand for digital infrastructure solutions, yet facing certain challenges in its operating environment.
  • The company demonstrated steady progress across multiple fronts, showing resilience and adaptability amid evolving market conditions.
  • On the positive side, Bentley Systems reported solid performance metrics with a 10.5% year-over-year ARR growth, or 11% excluding China, indicating robust demand for its digital solutions.

NIPPO LTD. (9913 JP): RESEARCH UPDATE

By Nippon Investment Bespoke Research UK

  • Nippo produced record earnings in FY25 1H, with OP of ¥946mil (+12.8% YoY) on sales of ¥22,186mil (+0.3% YoY).
  • While 1H sales remained flat YoY due to a decline in sales of the Electronics segment (-3.3% YoY), OP hit a semi-annual record, thanks to (1) solid growth of in-house products such as semiconductor wafer grinding carriers and (2) cost reductions in overseas factories.
  • FY25 is the final year of Nippo’s medium-term plan [MTP].

Qualcomm’s IoT Empire Is Booming — Can Arduino Supercharge Its $14B Vision?

By Baptista Research

  • Qualcomm Incorporated’s results for the fourth quarter of fiscal 2025 illustrate both the strategic advancements and challenges within its diverse business portfolio.
  • The company reported revenues of $11.3 billion and a non-GAAP earnings per share (EPS) of $3, surpassing their guidance expectations.
  • A sequential increase in QCT revenues, amounting to $9.8 billion, was primarily driven by strong customer demand for Snapdragon-powered Android handsets, substantial growth in automotive solutions, and robust performance in IoT sectors like industrial applications, Wi-Fi 7, and 5G.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Financials: Shanghai Shenzhen CSI 300 Index, Superbank, Ping An Bank Co Ltd A, TOPIX Banks Index, EURO/US DOLLAR, Speedy Hire Plc, Sunway Bhd, Papanets, Frasers Property Ltd, Urbanet Corp and more

By | Daily Briefs, Financials

In today’s briefing:

  • CSI 300 (SHSZ300) Tactical Outlook After Nov. 28 Rebalance Announcement
  • Superbank Pre-IPO: Strong Partnerships With Inflection Into Profitability
  • GEM Banks – 2026 High Conviction Ideas
  • Japanese Banks: TPNBNK Structural Sector Buy-Case, Preparing for Shinsei (8303) January Passive Flow
  • Comment on Exchange Rate EUR/USD October 24, 2025
  • Speedy Hire – Opportunity knocks
  • Primer: Sunway Bhd (SWB MK) – Nov 2025
  • (25 Nov 2025) Papanets(9388 JP) — Fisco Company Research
  • Primer: Frasers Property Ltd (FPL SP) – Nov 2025
  • (28 Nov 2025) Urbanet Corp(3242 JP) — Fisco Company Research


CSI 300 (SHSZ300) Tactical Outlook After Nov. 28 Rebalance Announcement

By Nico Rosti

  • On November 28th China Securities Index Co (CSI) announced the changes to the CSI 300 Index (SHSZ300 INDEX): 11 companies added and 11 deleted.
  • The complete list of additions and deletions is available here (or see the attachment at the end of this insight for your convenience).
  • We analyze our probabilistic models to forecast short-term market directions for the CSI 300 Index, as passive flows between here and December 12 may affect the index volatility and trend.

Superbank Pre-IPO: Strong Partnerships With Inflection Into Profitability

By Hong Jie Seow

  • Superbank (SUPA IJ) aims to raise around US$184m in its Indonesia IPO.
  • Superbank is a digital bank in Indonesia operating through a combination of ecosystem-led distribution and its own standalone mobile application. 
  • In this note, we look at its past performance and other deal dynamics that might impact the listing.

GEM Banks – 2026 High Conviction Ideas

By Victor Galliano

  • Our GEM bank top picks for 1H 2026 are Banrisul, Bradesco and Ping An Bank for very attractive fundamental valuations with healthy dividends and earnings growth potential
  • We also have buy recommendations on China Construction Bank (CCB) and Hana Financial, both of which are deep value plays relative to their returns, combined with sound balance sheets
  • Kotak Mahindra bank is our only sell recommendation for its premium valuation, even among Indian banks, relative to its underwhelming ROE prospects

Japanese Banks: TPNBNK Structural Sector Buy-Case, Preparing for Shinsei (8303) January Passive Flow

By Jay Cameron

  • Japanese banks are entering a new, structurally sound phase driven by the BoJ’s policy pivot, which is fundamentally elevating Net Interest Income and profitability.
  • Capital efficiency and mandatory corporate governance reforms are set to significantly close the P/B gap against global peers.
  • TOPIX Bank Index could be poised for continued outperformance over the broader market, making it an essential, high-conviction portfolio exposure as 8303 Shinsei returns to the index.

Comment on Exchange Rate EUR/USD October 24, 2025

By VRS (Valuation & Research Specialists)

  • During the period under consideration, i.e. September 25th, 2025 to October 24th, 2025, the EUR/USD pair exhibited a bearish trend.
  • In the beginning, it showed overall a downward slope, until October 14th where the pair indicated an upward trend.
  • After that, it fluctuated sideways between MA-10 and MA-20. By the end of the period the price it was slightly lower than the level of September 25th.

Speedy Hire – Opportunity knocks

By Equity Development

  • The new ProService Agreement is the dominant feature of year-to-date performance, driving an uplift in revenue and profitability despite subdued market conditions.
  • Velocity implementation continues, moving from enabling to growth phases.
  • While higher interest costs reduce FY26 estimates, the ProService deal materially enhances expected earnings thereafter, and we have raised our fair value to 61p per share to reflect this.

Primer: Sunway Bhd (SWB MK) – Nov 2025

By αSK

  • Sunway is a leading Malaysian conglomerate with a diversified business model spanning property development, construction, healthcare, and real estate investment, providing multiple revenue streams and resilience.
  • Recent performance highlights strong property sales, achieving 86% of the FY25 target, and an improving balance sheet with net gearing reduced to 0.35x. However, 9M25 core net profit fell below expectations due to slower progress billings in the construction segment.
  • Forward-looking catalysts include major property launches scheduled for 4Q25 and strategic expansion in the healthcare division to capture growing demand and medical tourism. The construction segment’s growth is supported by a robust order book, particularly in high-tech facilities like data centers.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


(25 Nov 2025) Papanets(9388 JP) — Fisco Company Research

By FISCO

Key points (machine generated)

  • Papanets (9388) is a service company listed on the Fukuoka Stock Exchange Q-Board in March 2025.
  • The company supports real estate management firms and related businesses with services like patrol, cleaning, and reporting through its system ‘Jun-kun.’
  • Papanets also offers comprehensive interior support, including furniture manufacturing, sales, delivery, and installation.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only.


Primer: Frasers Property Ltd (FPL SP) – Nov 2025

By αSK

  • Frasers Property is a geographically diversified real estate company with a significant presence across Singapore, Australia, Europe, and Southeast Asia, operating across residential, retail, commercial, industrial, and hospitality sectors.
  • The company is currently trading at a significant discount to its book value, with a Price-to-Book ratio of 0.43, suggesting a potential valuation gap. This is supported by a high Smartkarma Value score of 5/5.
  • Recent financial performance indicates headwinds, with both revenue and net income declining in the latest reported year. The company’s growth track record also shows negative trends over 3, 7, and 10-year periods for key metrics like revenue and EPS, signaling underlying challenges.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


(28 Nov 2025) Urbanet Corp(3242 JP) — Fisco Company Research

By FISCO

Key points (machine generated)

  • The briefing took place on January 28, 2025, featuring Nobuharu Hattori and investor DAIBOUCHOU.
  • The session is part of Urbanet Corporation’s presentation, listed on the Tokyo Stock Exchange in the real estate sector.
  • The introduction stresses the importance of reading disclaimers for careful consideration of the information.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: Bio Techne Corp, InxMed, Novo Nordisk, Penumbra , Soleno Therapeutics , Novartis , Elanco Animal Health and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Bio-Techne Braces for a Biotech Funding Revival—Is a Major Upswing Ahead?
  • Primer: InxMed (IXM HK) – Nov 2025
  • Novo Nordisk’s Wegovy Pill Strategy Is a Game-Changer—Inside the Big Bet!
  • Penumbra Ignites a Pulmonary Embolism Breakthrough—Hospitals Are Racing to Adopt It!
  • Primer: Soleno Therapeutics (SLNO US) – Nov 2025
  • Novartis’s $2.59 Million Itvisma Gets FDA Nod—Can It Conquer the SMA Market?
  • Elanco Animal Health: Adoption & Commercial Scaling of New Companion Animal Therapies & Key Growth Levers!


Bio-Techne Braces for a Biotech Funding Revival—Is a Major Upswing Ahead?

By Baptista Research

  • Bio-Techne delivered its first-quarter fiscal year 2026 results amidst a challenging market environment.
  • Despite the company’s strategic and disciplined efforts, organic revenue declined by 1%, primarily due to timing issues in their Cell Therapy business from large customers and the ongoing softness in biotech funding.
  • These timing issues were particularly impacted by FDA Fast Track Designations received by key customers that, while accelerating therapy approval timelines, reduced the near-term demand for reagents.

Primer: InxMed (IXM HK) – Nov 2025

By αSK

  • InxMed is a clinical-stage biotechnology company with a strategic focus on overcoming cancer drug resistance and metastasis, primarily targeting the Chinese market.
  • The company’s lead asset, Ifebemtinib (a FAK inhibitor), is being developed as a cornerstone of combination therapies across a range of solid tumors, a strategy that could unlock significant value where monotherapies have previously failed.
  • While the pipeline holds promise, InxMed faces substantial risks typical of a clinical-stage biotech, including the inherent uncertainty of clinical trial outcomes, a competitive landscape for its targeted pathways (FAK and FAP), and the financial risks associated with drug development.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Novo Nordisk’s Wegovy Pill Strategy Is a Game-Changer—Inside the Big Bet!

By Baptista Research

  • Novo Nordisk’s earnings report for the first nine months of 2025 reflects a complex financial and strategic landscape.
  • The company reported a 15% rise in sales and a 10% increase in operating profit.
  • The growth in sales was largely driven by the U.S. and international operations both showing robust performance, although the company has tempered future expectations by adjusting guidance to 8-11% sales growth and 4-7% for operating profit due to anticipated slower growth in its key GLP-1 treatments for diabetes and obesity.

Penumbra Ignites a Pulmonary Embolism Breakthrough—Hospitals Are Racing to Adopt It!

By Baptista Research

  • Penumbra, Inc. reported its financial results for the third quarter of 2025, delivering solid performance across its business segments.
  • The company achieved a total revenue of $354.7 million, marking a year-over-year increase of 17.8% on a reported basis and 16.9% in constant currency.
  • This growth illustrates progress in executing Penumbra’s strategy and enhancing its technological and market position.

Primer: Soleno Therapeutics (SLNO US) – Nov 2025

By αSK

  • Soleno Therapeutics has achieved a major milestone with the recent FDA approval of its lead drug, VYKAT™ XR (diazoxide choline extended-release tablets), for the treatment of hyperphagia (excessive hunger) in patients with Prader-Willi Syndrome (PWS). This marks the first approved therapy specifically for this debilitating symptom of the rare genetic disorder, representing a significant commercial opportunity.
  • The company is now transitioning to a commercial-stage entity, with the U.S. launch of VYKAT™ XR expected to commence in April 2025. This pivotal shift from a clinical-stage to a revenue-generating company is a key inflection point for Soleno.
  • While the FDA approval is a major de-risking event, the company’s future success will depend on a successful commercial launch, market adoption by physicians and patients, and navigating the competitive landscape of potential future treatments for PWS.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Novartis’s $2.59 Million Itvisma Gets FDA Nod—Can It Conquer the SMA Market?

By Baptista Research

  • The FDA’s recent green light for Novartis’s gene therapy Itvisma marks a major commercial and clinical milestone for the Swiss drugmaker.
  • Itvisma is an updated version of Zolgensma, previously limited to infants under age 2 with spinal muscular atrophy (SMA), and will now treat older patients aged 2 and up.
  • This approval significantly expands the addressable market for one of the rare commercial successes in the struggling gene therapy sector.

Elanco Animal Health: Adoption & Commercial Scaling of New Companion Animal Therapies & Key Growth Levers!

By Baptista Research

  • Elanco Animal Health’s third quarter of 2025 showcased a robust performance and a revised, optimistic outlook for the year, reflecting growth in several key areas while also indicating certain challenges.
  • The company reported a 9% organic constant currency growth in the quarter, surpassing the high end of their guidance for revenue, adjusted EBITDA, and adjusted EPS.
  • This marks the ninth consecutive quarter of total underlying growth, driven primarily by a 20% increase in U.S. Farm sales and 9% growth in U.S. Pet Health.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Consumer: Unilever PLC, China Yuhua Education, Dollar General, LG Electronics India, G 7 Holdings, Garden, Health And Happiness (H&H), Johnson Controls, Acushnet Holdings, Lucid Group and more

By | Consumer, Daily Briefs

In today’s briefing:

  • Unilever Spins Off Magnum Ice Cream: Index Changes Ahead
  • Primer: China Yuhua Education (6169 HK) – Nov 2025
  • DG US – DoorDash’s Massive Retail Bet—Can Pet Supplies and Electronics Deliver a Profit Surge?
  • LG Electronics (LGEINDIA IN): Global Index Inclusion Post-IPO
  • (28 Nov 2025) G 7 Holdings(7508 JP) — Fisco Company Research
  • (26 Nov 2025) Garden(274A JP) — Fisco Company Research
  • Lucror Analytics – Morning Views Asia
  • Johnson Controls Just Triggered a Strategic Shake-Up—Here’s the Inside Story!
  • Acushnet Is Expanding Worldwide—How Will Its Global Power Push Reshape the Golf Market?
  • Lucid Group: New Aggressive Power Moves With NVIDIA, Uber, & Nuro & Other Major Growth Drivers!


Unilever Spins Off Magnum Ice Cream: Index Changes Ahead

By Harry Kalfas

  • Unilever PLC (ULVR LN) is spinning off its Ice Cream business into a standalone publicly-listed company, The Magnum Ice Cream Company (“TMICC”).
  • TMICC is expected to list in early December 2025, trading under the ticker “MICC” on Euronext Amsterdam, LSE and NYSE.
  • Significant index implications across EU and Global indices, on an intra-quarter basis.

Primer: China Yuhua Education (6169 HK) – Nov 2025

By αSK

  • China Yuhua Education is a prominent private education provider in China, focusing on higher education and secondary education. The company has faced significant headwinds due to regulatory changes in the Chinese education sector but has shown resilience by adapting its business model.
  • The company’s financial performance has been impacted by the deconsolidation of its K-9 assets in 2021, a direct consequence of the new regulations. However, recent results indicate a recovery, with revenue and adjusted net profit showing growth.
  • The future outlook for China Yuhua Education is cautiously optimistic. While regulatory risks remain a significant concern, the company’s focus on higher and vocational education, which are more supported by government policies, could provide a pathway for sustainable growth.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


DG US – DoorDash’s Massive Retail Bet—Can Pet Supplies and Electronics Deliver a Profit Surge?

By Baptista Research

  • DoorDash recently held an earnings call discussing its third-quarter 2025 financial results and strategic initiatives.
  • CEO Tony Xu and CFO Ravi Inukonda outlined the company’s current performance and future plans.
  • One of the central topics was DoorDash’s investment plans for 2026, which include several hundred million dollars allocated to technology and product development.

LG Electronics (LGEINDIA IN): Global Index Inclusion Post-IPO

By Dimitris Ioannidis

  • LG Electronics (LGEINDIA IN) went public on 14 October 2025 on NSE and has a current market cap of over $12bn.
  • Inclusion in Global All-World is expected in June 2026 as it passes eligibility and thresholds.
  • Earliest possible inclusion in Global Standard is February 2026; however, it is currently estimated to fail the float cap threshold.

(28 Nov 2025) G 7 Holdings(7508 JP) — Fisco Company Research

By FISCO

Key points (machine generated)

  • G-7 Holdings is expanding its meat business through mergers and acquisitions to achieve record profits by March 2026.
  • The company reported consolidated sales of 110.7 billion yen, a 9.6% increase year-over-year, and an ordinary profit of 3.3 billion yen, up 7.5%.
  • Strong performance is driven by sales in automotive-related and Gyomu Super businesses, along with contributions from new subsidiaries.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only.


(26 Nov 2025) Garden(274A JP) — Fisco Company Research

By FISCO

Key points (machine generated)

  • FISCO Ltd. projects a double-digit profit increase for Garden Co. in the second half of fiscal year ending February 2026.
  • Garden Co. operates 197 restaurant locations, primarily in Tokyo’s terminal stations, offering diverse formats like ramen and izakayas.
  • Popular flagship offerings include ‘Ikkyakuya’ ramen and ‘Yamashita Honki Udon,’ appealing especially to young male customers.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only.


Lucror Analytics – Morning Views Asia

By Leonard Law, CFA

  • In today’s Morning Views publication we comment on developments of the following high yield issuers: Health and Happiness (H&H)
  • China’s industrial profits fell 5.5% y-o-y in October, reversing from the sharp double-digit growth in September and August. Industrial profits grew 1.9% in 10M/25, decelerating from 3.2% in 9M.
  • Profits from the high-tech sector remained robust at 8.0% in 10M, with profits from smart unmanned aircraft and smart in-vehicle equipment registering triple-digit growth.

Johnson Controls Just Triggered a Strategic Shake-Up—Here’s the Inside Story!

By Baptista Research

  • Johnson Controls’ fourth quarter of fiscal year 2025 results highlight a year marked by growth and strategic advancements, coupled with continued efforts towards operational efficiency.
  • Sales growth of 6% and a 17% increase in adjusted earnings per share (EPS) indicate strong performance, though challenges and opportunities are balanced.
  • A significant highlight is the attainment of a 102% free cash flow conversion, bolstered by rigorous working capital management and operational efficiencies.

Acushnet Is Expanding Worldwide—How Will Its Global Power Push Reshape the Golf Market?

By Baptista Research

  • Acushnet Holdings Corp. reported a solid performance for the third quarter of 2025, with net sales totaling $658 million, representing a 5% increase on a constant currency basis compared to the previous year.
  • This growth was observed across all segments.
  • The company’s adjusted EBITDA reached $119 million, which marks a 10% increase from the prior year, with year-to-date net sales amounting to $2.08 billion, reflecting a 4% growth.

Lucid Group: New Aggressive Power Moves With NVIDIA, Uber, & Nuro & Other Major Growth Drivers!

By Baptista Research

  • Lucid Group’s third quarter 2025 financial results illustrate a period of both significant achievements and challenges, showcasing a complex picture for current and prospective investors.
  • The company reported a seventh consecutive quarter of record vehicle deliveries, a testament to steady demand and operational resilience.
  • Revenue increased to $337 million, representing a 68% year-over-year growth, propelled by higher deliveries and a more favorable product mix that saw an increase in average selling prices.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Quantitative Analysis: ASX Short Interest Weekly (Nov 21st): James Hardie Industries and more

By | Daily Briefs, Quantitative Analysis

In today’s briefing:

  • ASX Short Interest Weekly (Nov 21st): James Hardie Industries, Atlas Arteria, Sonic Healthcare


ASX Short Interest Weekly (Nov 21st): James Hardie Industries, Atlas Arteria, Sonic Healthcare

By Ke Yan, CFA, FRM

  • We analyzed the changes in short interest of ASX Stocks as of Nov 21st (reported today). The aggregated short interest was USD26.3bn.
  • We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases & decreases in short value, short as multiple of ADT.
  • We highlight short interest changes in James Hardie Industries, Atlas Arteria, Sonic Healthcare, Coles, Life360.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Australia: Percheron Therapeutics and more

By | Australia, Daily Briefs

In today’s briefing:

  • Percheron Therapeutics — Phase II visibility drives valuation upgrade
  • Percheron Therapeutics — Phase II visibility drives valuation upgrade


Percheron Therapeutics — Phase II visibility drives valuation upgrade

By Edison Investment Research

We have refreshed our investment case for Percheron as the company heads into CY26 with a clearly defined Phase II plan for HMBD-002, backed by positive Phase I data and a strengthened management team. Our model now reflects the likely Phase II basket design, comprising exploratory and subsequent expansion cohorts, along with refined assumptions on study size, sequencing and timelines across the four priority indications: triple-negative breast cancer (TNBC), EGFR-mutant non-small cell lung cancer (NSCLC), HER2-negative oesophageal adenocarcinoma and endometrial cancer. With trial initiation likely to be staggered (we model a three- to six-month gap between each arm), we anticipate TNBC and NSCLC to be the lead indications, reflecting their larger addressable markets and clearer early-stage partnering interest. We expect the company to self-sponsor the Phase II studies with a global licensing deal in 2029, ahead of Phase III. Our valuation increases to A$79.0m or 7.3c/share, from A$66.7m or 6.1c/share.


Percheron Therapeutics — Phase II visibility drives valuation upgrade

By Edison Investment Research

We have refreshed our investment case for Percheron as the company heads into CY26 with a clearly defined Phase II plan for HMBD-002, backed by positive Phase I data and a strengthened management team. Our model now reflects the likely Phase II basket design, comprising exploratory and subsequent expansion cohorts, along with refined assumptions on study size, sequencing and timelines across the four priority indications: triple-negative breast cancer (TNBC), EGFR-mutant non-small cell lung cancer (NSCLC), HER2-negative oesophageal adenocarcinoma and endometrial cancer. With trial initiation likely to be staggered (we model a three- to six-month gap between each arm), we anticipate TNBC and NSCLC to be the lead indications, reflecting their larger addressable markets and clearer early-stage partnering interest. We expect the company to self-sponsor the Phase II studies with a global licensing deal in 2029, ahead of Phase III. Our valuation increases to A$79.0m or 7.3c/share, from A$66.7m or 6.1c/share.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief South Korea: Korea Stock Exchange KOSPI 200 and more

By | Daily Briefs, South Korea

In today’s briefing:

  • Korea FSC Omnibus Rollout Dropped Today: Key Backdrop & Trade-Relevant Angle


Korea FSC Omnibus Rollout Dropped Today: Key Backdrop & Trade-Relevant Angle

By Sanghyun Park

  • FSC confirms December rollout; beyond procedural cleanup, this structural shift in flows brings small-to-mid shops and offshore retail, creating new order patterns in the local market.
  • Omnibus accounts aggregate orders under one broker, blurring classic smart-money signals, slowing local retail follow-ons, and creating wider price-action gaps in the order book.
  • MSCI volatility trades also require attention; the omnibus rollout will likely intensify flows as new accounts follow major institutions, impacting the Korea sleeve short-term.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ECM: Xiao Noodles (XNC HK) IPO: Volume Growth Play Make This Noodles Joint Savoury Enough and more

By | Daily Briefs, ECM

In today’s briefing:

  • Xiao Noodles (XNC HK) IPO: Volume Growth Play Make This Noodles Joint Savoury Enough


Xiao Noodles (XNC HK) IPO: Volume Growth Play Make This Noodles Joint Savoury Enough

By Tina Banerjee

  • Guangzhou Xiao Noodles Catering Management (XNC HK) launched its Hongkong IPO aiming to raise up to HK$686M. The company plans to sell 97.4M shares at HK$5.64-$7.04 per share.
  • Xiao Noodles are a Chinese noodle restaurants operator in China. They operate the Xiao Noodles brand in the Chinese Mainland and Hong Kong SAR.
  • The growth outlook quite justifies the incremental valuation. We think Xiao Noodles issue is attractively priced and investors can surely look to have a share in this secular growth story.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Thematic (Sector/Industry): Ohayo Japan | Grateful for Gains and more

By | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

  • Ohayo Japan | Grateful for Gains
  • Asia Real Estate Tracker (27-Nov-2025): KKR and Gaw sold Hyatt Regency Tokyo for over $813M.
  • Singapore Market Roundup (27-Nov-2025): UOB Kay Hian rates Soon Hock Enterprise a ‘buy’ at 68
  • Rare Earths 2025: Improving Fundamentals, Limited Valuation Headroom
  • Exencial Industry Tidings 27/11/2025
  • India Life Insurance Sector: Post-GST Rebound, Margin Expansion, and Structural Tailwinds


Ohayo Japan | Grateful for Gains

By Mark Chadwick

  • Nikkei Futures marginally lower with few new drivers given US holidays. Japan volumes likely to remain subdued
  • China/Japan tensions, tech outperformance, US rate cuts, BoJ’s dovish stance – stock supportive  
  • UK retailer Halfords’ strong cycling revenue suggests Shimano may benefit from inventory restocking by retailers in 2H, preparing for next summer’s peak demand.

Asia Real Estate Tracker (27-Nov-2025): KKR and Gaw sold Hyatt Regency Tokyo for over $813M.

By Asia Real Estate Tracker

  • KKR and Gaw Capital Partners have sold the Hyatt Regency Tokyo for over $813 million.
  • The partnership is also acquiring six logistics parks in India for a total of $336 million.
  • JD.com’s logistics management unit has received approval for a potential $500 million IPO in Hong Kong.

Singapore Market Roundup (27-Nov-2025): UOB Kay Hian rates Soon Hock Enterprise a ‘buy’ at 68

By Singapore Market Roundup

  • UOB Kay Hian initiates ‘buy’ on Soon Hock Enterprise, targeting 68 cents.
  • RHB’s Yeo lowers Thai Beverage target price to 62 cents, forecasts FY2026 improvement.
  • Geo Energy’s 3QFY2025 disappoints; Chew keeps 59 cents target price.

Rare Earths 2025: Improving Fundamentals, Limited Valuation Headroom

By Rahul Jain

  • CNRE delivered strong H1 results and downstream momentum, but its valuation remains elevated even after the pullback.
  • Shenghe offers superior risk-adjusted value with cleaner pricing leverage and materially lower multiples.
  • Lynas still trades on geopolitical scarcity, not earnings strength, making it suitable only as strategic optionality.

Exencial Industry Tidings 27/11/2025

By Viral Kishorchandra Shah

  • Marine product exports rise by 16 % during April-October 2025
  • Kharif output for 2025-26 expected to rise by 2.3%: First advance estimates
  • Global specialty chemicals market estimated at USD 1.2 trillion in 2025

India Life Insurance Sector: Post-GST Rebound, Margin Expansion, and Structural Tailwinds

By Sudarshan Bhandari

  • The Indian life insurance sector saw a powerful recovery in October 2025 following a temporary Q2 slowdown, driven by the GST exemption structural tailwind. 
  • Q2 FY26 was marked by broad-based Value of New Business (VNB) margin expansion, signaling a successful shift toward higher-margin non-par savings and protection products.
  • Despite a temporary drag on Embedded Value (EV) from Input Tax Credit (ITC) loss, management is confident of strong H2 FY26 growth based on the GST boost and product mix.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Singapore: Alliance Healthcare Group Ltd, Asian Healthcare Specialists, Centurion Accommodation REIT and more

By | Daily Briefs, Singapore

In today’s briefing:

  • Primer: Alliance Healthcare Group Ltd (AHG SP) – Nov 2025
  • Primer: Asian Healthcare Specialists (AHSP SP) – Nov 2025
  • Primer: Centurion Accommodation REIT (CAREIT SP) – Nov 2025


Primer: Alliance Healthcare Group Ltd (AHG SP) – Nov 2025

By αSK

  • Alliance Healthcare Group (AHG) is an integrated healthcare provider in Singapore, strategically positioned to capitalize on favorable industry tailwinds, including an aging population and increasing demand for digital health services.
  • The company’s growth is driven by its diversified business segments, encompassing Managed Healthcare Solutions, GP and Specialist Clinics, Pharmaceutical Services, and a growing Mobile and Digital Health division.
  • While demonstrating strong revenue growth, the company faces challenges related to rising operating costs and investments in new ventures that are currently impacting profitability.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Primer: Asian Healthcare Specialists (AHSP SP) – Nov 2025

By αSK

  • Multi-disciplinary Specialist Group with Regional Aspirations: Asian Healthcare Specialists (AHS) is a growing multi-disciplinary medical services group in Singapore, offering a wide range of specialised healthcare services. Initially focused on orthopaedics, the company has expanded through organic growth and acquisitions to include anaesthesia, dermatology, gastroenterology, ophthalmology, urology, and family medicine. A key part of its strategy is to export the Singapore brand of high-quality healthcare to the region, with an initial foray into Myanmar.
  • Experienced Medical Professionals Driving Quality Care: The group’s strength lies in its team of experienced medical professionals, with many having over 20 years of experience in both public and private healthcare sectors. This deep expertise allows AHS to focus on providing ethical, high-quality, and patient-centric care, which is a core tenet of its business philosophy. The company aims to provide a comprehensive suite of in-house services for complex medical issues that require input from various specialities.
  • Favorable Industry Tailwinds Supporting Growth: AHS is well-positioned to benefit from favorable demographic and industry trends in Singapore. An ageing population is expected to drive demand for healthcare services, particularly in areas like orthopaedics. Furthermore, rising income levels, a growing number of insured patients, and Singapore’s reputation as a regional healthcare hub are expected to contribute to the growth of the private healthcare market.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Primer: Centurion Accommodation REIT (CAREIT SP) – Nov 2025

By αSK

  • Centurion Accommodation REIT (CAREIT) is Singapore’s first publicly listed real estate investment trust with a pure-play focus on specialized accommodation assets, specifically Purpose-Built Worker Accommodation (PBWA) in Singapore and Purpose-Built Student Accommodation (PBSA) in the United Kingdom and Australia.
  • The REIT benefits from a strong, committed sponsor, Centurion Corporation Limited, which is the largest PBWA operator in Singapore. This relationship provides a robust pipeline for future growth, operational expertise, and significant alignment of interests, with the sponsor retaining a substantial stake post-IPO.
  • CAREIT exhibits a compelling financial profile characterized by high initial portfolio occupancy (over 96%), strong revenue and net income growth, and an attractive forward distribution yield, underpinned by a commitment to distribute 100% of its distributable income until 2027.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars